Conflicting results exist on targeting the low-affinity adenosine A2B receptor (A2BAR) for the treatment of PAH mostly because it displays dual roles in acute vs. chronic lung diseases. This evidence concerns the gene ADORA2B and pulmonary arterial hypertension.